Drugs.com - New Drug Approvals

FDA Approves Omlyclo (omalizumab-igec), an Interchangeable Biosimilar to Xolair

JERSEY CITY, N.J., March 9, 2025 /PRNewswire/ -- Celltrion today announced the U.S. Food and Drug Administration (FDA) approved Omlyclo® (omalizumab-igec) as the first and only biosimilar designated as interchangeable with Xolair&reg...

Apr 26, 2025 - 14:51
 0
FDA Approves Omlyclo (omalizumab-igec), an Interchangeable Biosimilar to Xolair
JERSEY CITY, N.J., March 9, 2025 /PRNewswire/ -- Celltrion today announced the U.S. Food and Drug Administration (FDA) approved Omlyclo® (omalizumab-igec) as the first and only biosimilar designated as interchangeable with Xolair®...
Read More

Tags:

Previous Article

FDA Approves Arbli (losartan potassium) Oral Suspension as the First Ready-to-Us...

Next Article

scPharmaceuticals Announces FDA Approval of Supplemental New Drug Application Ex...

Related Posts

ANI Pharmaceuticals Announces FDA Approval for Expansion of Iluvien Label

ANI Pharmaceuticals Announces FDA Approval for Expansio...

Apr 26, 2025  0

Argenx Announces FDA Approval of Vyvgart Hytrulo Prefilled Syringe for Self-Injection

Argenx Announces FDA Approval of Vyvgart Hytrulo Prefil...

Apr 26, 2025  0

FDA Approves Opdivo (nivolumab) + Yervoy (ipilimumab) as a Treatment for Patients with Previously Untreated Microsatellite Instability-High or Mismatch Repair Deficient Unresectable or Metastatic Colorectal Cancer

FDA Approves Opdivo (nivolumab) + Yervoy (ipilimumab) a...

Apr 26, 2025  0